Selective LXR inverse agonist. Exhibits no significant activity at other nuclear receptors at maximally effective concentration. Inhibits the Warburg effect and lipogenesis by down-regulation of LXR-mediated gene expression. Selectively reduces cell viability and induces apoptosis in cancer cell lines in vitro. Suppresses hepatic steatosis and inhibits growth of tumor xenografts in mice.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 626.62. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.6 mL||7.98 mL||15.96 mL|
|5 mM||0.32 mL||1.6 mL||3.19 mL|
|10 mM||0.16 mL||0.8 mL||1.6 mL|
|50 mM||0.03 mL||0.16 mL||0.32 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Flaveny et al (2015) Broad anti-tumor activity of a small molecule that selectively targets the Warburg effect and lipogenesis. Cancer Cell. 28 42 PMID: 26120082
If you know of a relevant reference for SR 9243, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: SR 9243, supplier, SR9243, selective, LXR, inverse, agonists, agonism, lipogenesis, Warburg, effect, LXR-like, Receptors, Tocris Bioscience
Citations for SR 9243
Citations are publications that use Tocris products.
Currently there are no citations for SR 9243. Do you know of a great paper that uses SR 9243 from Tocris? If so please let us know.